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Abstract The application of human stem cell technology of-
fers theoretically a great potential to treat various human dis-
eases. However, to achieve this goal a large number of scien-
tific issues remain to be solved. Cell surface carbohydrate
antigens are involved in a number of biomedical phenomena
that are important in clinical applications of stem cells, such as
cell differentiation and immune reactivity. Due to their cell
surface localization, carbohydrate epitopes are ideally suited
for characterization of human pluripotent stem cells. Amongst
the most commonly used markers to iden- tify human plurip-
otent stem cells are the globo-series glycosphingolipids
SSEA-3 and SSEA-4. However, our knowledge regarding
human pluripotent stem cell glycosphingolipid expression
was until recently mainly based on immunological assays of
intact cells due to the very limited amounts of cell material
available. In recent years the knowledge regarding
glycosphingolipids in human embryonic stem cells has been
extended by biochemical studies, which is the focus of this
review. In addition, the distribution of the human pluripotent
stem cell glycosphingolipids in human tissues, and
glycosphingolipid changes during human stem cell differenti-
ation, are discussed.
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Background
The successful isolation of mouse embryonic stem cells [1, 2],
and subsequently human embryonic stem cells (hESC) [3],
from the inner cell mass of the blastocyst are milestones in
regenerative medicine and life science. Takahashi’s and
Yamanaka’s equally important contributions generating so-
called induced pluripotent stem cells, initially from mouse
[4], and thereafter from human [5] fibroblasts, by retrovirus-
mediated transfection, expanded the field further. These find-
ings theoretically enable new therapeutic alternatives and clin-
ical applications based on an unlimited and renewable source
of cells. Regardless of origin, both hESC and human induced
pluripotent stem cells (hiPSC) possess the ability to be prop-
agated indefinitely in culture and the capacity to generate cells
of each of the three embryonic germ layers (endoderm, meso-
derm and ectoderm), hence differentiate into any human cell
type (reviewed in ref. [6]). Pluripotent stem cells (including
both hESC and hiPSC) and their derivatives provide models
for studying developmental biology and pathology, as well as
for the development of novel drugs, toxicology screening, and
in the future cell/organ transplantation therapies.
The increasing population of people worldwide suffering
from chronic diseases and organ failure are great medical
challenges. The successful derivation of insulin-producing β
cells, cardiomyocytes, hepatocytes and neurons from pluripo-
tent stem cells could eventually provide potential cures.
However, there are many obstacles to overcome before stem
cell therapy can be brought to the clinic. Pluripotent stem cells
may not function normally in vivo, might retain tumorigenic
potential, and the immune system of a recipient grafted with
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human stem cell derived cells/tissues will be challenged with
non-self antigens which might lead to rejection, necessitating
a life-long immunosuppressive therapy of the recipient. On
the other hand, if hiPSC from the specific patient can be used,
immune rejection may be eliminated.
Initially, human pluripotent stem cells were cultivated on
mouse embryonic feeder cells, consequently potentially
risking incorporation of animal components into the human
cells, which further potentiates the immunogenicity of the
grafts and aggravates the risk for rejection. In recent years
technical development of media and culturing materials has
made it possible to culture pluripotent cells and their deriva-
tives under feeder- and xeno-free conditions [7]. This progress
enables the production/development of Good-Manufacturing-
Practice cell lines, and takes the stem cell research field closer
to clinical practice.
Embryonic stem cell markers
The rapid development in the stem cell field requires a parallel
rapid progress in stem cell quality control, both of undifferen-
tiated cells and cells after derivation and expansion. The ex-
pression of certain cell surface markers has been used for
characterization since the first successful isolation of human
embryonic stem cells [3]. Several of these stem cell markers
are carbohydrates, as e.g. the tumor recognition antigens
TRA-1-60 and TRA-1-81, and the stage-specific embryonic
antigens SSEA-3 and SSEA-4 [8]. Recently, the blood group
H type 1 epitope/SSEA-5 and the sialyl-lactotetra epitope
were identified as novel carbohydrate markers of human plu-
ripotent stem cells (hPSC) [9, 10]. The blood group H type 1
and the sialyl-lactotetra epitopes can be found on both glyco-
proteins and glycosphingolipids, whereas the globo-series de-
terminants SSEA-3 and SSEA-4 have hitherto only been iden-
tified in glycosphingolipids.
However, although SSEA-3 and SSEA-4 are used as
markers of undifferentiated hPSC, these glycosphingolipids
are also present in some adult human tissues [11–13].
Glycosphingolipids
In eukaryotic cells glycosphingolipids are predominantly
found on the cell surface, with the lipophilic ceramide part
located in the outer membrane leaflet and the carbohydrate
part exposed to the surrounding environment [14]. The
expression of glycosphingolipids varies both quantitatively
and qualitatively between different species, individuals of
the same species, organs and individual cells within an
organ. The ceramide part consists of a fatty acid and a
long-chain base, united by an amide linkage and a great
number of molecular species results due to variations of the
number of carbon atoms, double bonds, methyl branches
and hydroxyl groups. The saccharide chain is attached, by
a glycosidic linkage, to the primary hydroxyl group of the
long-chain base. The size of the carbohydrate moiety nor-
mally ranges from 1 to 12 monosaccharide units, but
glycosphingolipids with more than 30 saccharide residues
(polyglycosylceramides) have been described. The oligo-
saccharide part exhibits a great complexity due to variation
of the constituent monosaccharides, binding positions,
glycosidic configuration, carbohydrate sequence and
branching. When all the possible variations of the ceramide
as well as the carbohydrate moiety are taken into account,
an enormous potential structural complexity emerges [15].
More than 400 compounds are listed in a summary of iden-
tified glycosphingolipids [16].
Glycosphingolipids are divided into acid (negatively
charged) and non-acid (neutral) components, where the acid
glycosphingolipids are further divided into sulfate ester con-
jugated (sulfatides) and sialic acid containing structures
(gangliosides). In addition, glycosphingolipids are classified
on the basis of their carbohydrate core structures. In humans
the lacto/type 1 (Galβ3GlcNAc), neolacto/type 2
(Galβ4GlcNAc), and globo/type 4 (Galα4Gal) core chains
are the most common in non-acid glycosphingolipids, while
gangliosides are mainly based on ganglio (Galβ3GalNAc) or
neolacto core chains. The lacto and neolacto core chains are
also present in glycoproteins, but the globo and ganglio
core structures have hitherto only been identified in
glycosphingolipids.
Several different isolation and analytical techniques are
needed to achieve a complete structural characterization
of glycosphingolipids from biological materials .
Glycosphingolipids have to be isolated, and separated into
non-acid components, gangliosides and sulfolipids, which
thereafter need to be separated into individual molecular spe-
cies [17]. Analytical techniques encompass mass spectrome-
try, NMR spectroscopy, chemical degradation and immuno-
staining [18]. To achieve this, substantial amounts of starting
tissue material are required. When only small amounts of bi-
ological material are available, such as in vitro cultured cells
and tissue biopsies, the isolation procedure has to be modified
and analytical techniques restricted to immune assays and
mass spectrometry. These simplified procedures usually elim-
inate certain glycosphingolipid species, and remaining non-
glycosphingolipid contaminants hamper interpretation of the
analytical data. Since cross-reactivity is a well-known phe-
nomenon when using monoclonal antibodies directed against
glycan epitopes [19], including the antibodies directed to
SSEA-3 and Globo H [20], a cautious interpretation of the
results obtained is necessary. Hence, the structural information
gained is reduced, and there is an obvious risk of missing
individual glycosphingolipids as well as confusing different
structural components.
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Glycosphingolipid composition of hESC
In the first studies of hESC glycosphingolipids Liang et al.
used flow cytometry,MALDI-MS andMS/MS to characterize
glycosphingolipids from the upper phase obtained by Folch
partition of crude lipid extracts [21, 22]. This allowed identi-
fication of non-acid glycosphingolipids of the globo series
(globotetraosylceramide, globopentaosylceramide/SSEA-3
and the Globo H hexaosylceramide) and lacto series (type 1
core chain; lactotetraosylceramide and H type 1
pentaosylceramide). The gangliosides found were GM3,
GM1, GD1a or GD1b, sialyl-globopentaosylceramide/
SSEA-4 and d i - s i a ly l -g lobopen taosy lce ramide .
Glycosphingolipids identified and their structures are given
in Table 1.
Glycosphingolipidswere also characterized byMALDI-TOF/
TOF MS of oligosaccharides released from glycosphingolipids
by enzyme treatment in a highly ambitious study of the total
cellular glycome (glycosaminoglycans, N- and O-linked saccha-
rides, and glycosphingolipids) of human pluripotent stem cell
lines (hESC and hiPSC) [23]. However, in this study the cells
were cultured on mouse feeder cells. Culture of hESC in the
presence of animal-derived compounds may lead to uptake of
compounds from the culturemedium, as e.g. the nonhuman sialic
acid NeuGc [24], and feeder cells may also have contaminated
the human stem cell preparations. Thus, the interpretation of data
was challenging in this case. After eliminating glycan structures
that were probably of mouse origin, it was concluded that com-
pared to human somatic cells, the human stem cells had a higher




neolactotetraosylceramide, globotetraosylceramide, the NeuGc-
GM1 ganglioside, and gangliotriaosylceramide. Thus, the list of
characterized stem cell glycosphingolipids still contains some
compounds that are likely to be contaminants from the feeder
cells or culture medium, as e.g. the non-human ganglioside
NeuGc-GM1.
In order to allow characterization ofminor glycosphingolipids
of hESC and ident i fy novel s tem cel l markers ,
glycosphingolipids from two hESC lines (SA121, SA181) were
isolated using a large number of cells (1x109 cells per cell line) as
startingmaterial [10, 20]. These cells were grownwithout animal
derived material in the culture medium [7]. After chloroform/
methanol extraction and mild alkaline methanolysis, followed
by repeated column chromatographies of both native compounds
and acetylated derivatives, approximately 2.5 mg of total
acid glycosphingolipids and 3 mg of total non-acid
glycosphingolipids were obtained from each cell line. After ini-
tial structural characterization, the total acid and total non-acid
fractions were separated on silicic acid columns into partly puri-
fied sub-fractions, allowing a further characterization of minor
glycosphingolipid compounds. Structural determination was car-
ried out with complementary techniques, including thin-layer
chromatogram binding assays, LC-ESI/MS of native
glycosphingolipids and glycosphingolipid-derived oligosaccha-
rides, and proton NMR spectroscopy. In addition, the cellular
distribution of selected carbohydrate structures was studied by
flow cytometry, immunohistochemistry and immune electron
microscopy. By combining the data obtained by these analytical
methods, a complex expression of variant glycosphingolipids
was found, and several hESC glycosphingolipids, not previously
described, were identified (Table 1) [10, 20]. Thus, in addition to
the globo series and type 1 core chain glycosphingolipids previ-
ously characterized, a number of non-acid type 2 core chain
glycosphingolipids (neolactotetraosylceramide, the H type 2
pentaosylceramide, the Lex pentaosylceramide, and the Ley
hexaosylceramide) were identified, and also the blood group A
type 1 hexaosylceramide. Novel acid hESC glycosphingolipids
identified were sulfatide, sulf-lactosylceramide, sulf-
globopentaosylceramide, sialyl-globotetraosylceramide and
sialyl-lactotetraosylceramide.
Furthermore, a number of short chain glycosphingolipids
were identified as glucosylceramide, galactosylceramide,
lactosylceramide, galabiaosylceramide, lactotriaosylceramide
and globotriaosylceramide. These compounds, along with part
of the more polar ones (4–6 carbohydrate residues), are
retained in the lower phase after Folch partitioning.
Therefore, in studies using organic solvent/water partition
as part of the isolation procedure [21, 22], these
glycosphingolipids are not included. For the negatively
charged gangliosides, the major part of the short chain com-
pounds (≥3 carbohydrate residues) is found in the upper
phase.
Acid glycosphingolipids of hESC
Sulfated glycosphingolipids
Analyses of the acid glycosphingolipids of hESC by antibody
binding and LC-ESI/MS identified sulfatide and sulfated
lactosylceramide [10]. Sulfatide, and to some extent sulf-
lactosylceramide, are present in several normal human tissues,
as e.g. brain, kidney, gastro-intestinal tract including pancreas,
and trachea (reviewed in ref. [25]).
Sulfated glycosphingolipids were not found in the studies
of hESC glycosphingolipids by Liang et al. [21, 22]. This
is mostly likely due to the use of permethylated
glycosphingolipid derivatives in the mass spectrometric anal-
ysis, since sulfate groups are lost upon permethylation. In a
similar manner, sulfatide was not reported in the study by
Fujitani et al., since MALDI-TOF mass spectrometry in the
positive ion mode was used for characterization of the
glycosphingolipid-derived oligosaccharides [23].
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No sulfatide/sulf-lactosylceramide was detected on the cell
surface of hESC using the anti-SO3-3Galβ antibody in flow
cytometry, and immunohistochemistry showed only a faint
cytoplasmic staining. Furthermore, immune electron micros-
copy with the anti-sulfatide antibody O4 gave no staining of
the hESC cell surface, whereas a distinct staining ofmitochon-
dria and Golgi, was obtained. Sulfatide is a marker of imma-
ture oligodendrocytes [26], and the binding of this sulfatide
recognizing antibody O4 is used to monitor hESC and hiPSC
differentiation into oligodendrocytes, where it is detected after
four weeks of differentiation [27]. Interestingly, our findings
demonstrate that sulfatide is produced already in undifferenti-
ated hESC, but is retained within intracellular compartments.
Thus, upon oligodendrocyte differentiation there is a change
in the subcellular distribution of sulfatide, which should be
further investigated.
Table 1 Glycosphingolipids of human embryonic stem cells
No. trivial name Structure Methodsa References
Simple compounds
1. Galactosylceramide2 Galβ1Cer TLC, MS, NMR [20]
2. Glucosylceramide Glcβ1Cer TLC, MS, NMR [20]
3. Sulfatide SO3-3Galβ1Cer TLC, CBA, MS, IH, EM [10]
4. LacCer Galβ4Glcβ1Cer TLC, MS, NMR [20]
5. Sulf-LacCer SO3-3Galβ4Glcβ1Cer TLC, CBA, MS, IH, EM [10]
6. Galabiaosylceramide Galα4Galβ1Cer TLC, MS, NMR [20]
7. Lactotri GlcNAcβ3Galβ4Glcβ1Cer MS [20, 23]
8. GM3 NeuAcα3Galβ4Glcβ1Cer MS [10, 21]
9. GD3 NeuAcα8NeuAcα3Galβ4Glcβ1Cer MS [10]
Globoseries
10. Globotri Galα4Galβ4Glcβ1Cer MS, NMR [20]
11. Globotetra GalNAcβ3Galα4Galβ4Glcβ1Cer MS, NMR [20, 21, 23]
12. Globopenta/SSEA-3 Galβ3GalNAcβ3Galα4Galβ4Glcβ1Cer CBA, MS, NMR, FC, IF [20, 21, 23]
13. GloboH Fucα2Galβ3GalNAcβ3Galα4Galβ4Glcβ1Cer CBA, MS, NMR, FC, IF [20, 21]
14. Sialyl-globotetrab NeuAcα3GalNAcβ3Galα4Galβ4Glcβ1Cer MS [10]
15. Sialyl-globopenta/SSEA-4 NeuAcα3Galβ3GalNAcβ3Galα4Galβ4Glcβ1Cer CBA, MS, FC, IF [10, 21, 23]
16. Disialyl-globopenta NeuAcα3Galβ3(NeuAcα6)GalNAcβ3Galα4Galβ4Glcβ1Cer MS [10, 21]
17. Sulf-globopenta SO3-3Galβ3GalNAcβ3Galα4Galβ4Glcβ1Cer MS [10]
Lactoseries
18. Lactotetra Galβ3GlcNAcβ3Galβ4Glcβ1Cer MS, NMR, FC [20–22]
19. H type 1 penta/SSEA-5 Fucα2Galβ3GlcNAcβ3Galβ4Glcβ1Cer CBA, MS, NMR, FC [20, 21, 23]
20. A type 1 hexa GalNAcα3(Fucα2)Galβ3GlcNAcβ3Galβ4Glcβ1Cer CBA, MS [20]
21. Sialyl-lactotetra NeuAcα3Galβ3GlcNAcβ3Galβ4Glcβ1Cer CBA, MS, FC, IH, EM [10]
Neolactoseries
22. Neolactotetra Galβ4GlcNAcβ3Galβ4Glcβ1Cer CBA, MS [20, 23]
23. Neolactopenta HexNAc-Galβ4GlcNAcβ3Galβ4Glcβ1Cer MS [23]
24. H type 2 penta Fucα2Galβ4GlcNAcβ3Galβ4Glcβ1Cer MS [20]
25. Lex penta Galβ4(Fucα3)GlcNAcβ3Galβ4Glcβ1Cer MS [20]
26. Ley hexa Fucα2Galβ4(Fucα3)GlcNAcβ3Galβ4Glcβ1Cer CBA, MS [20, 23]
27. Lex hepta Galβ4(Fucα3)GlcNAcβ3Galβ4GlcNAcβ3Galβ4Glcβ1Cer CBA, MS [20]
28. Ley octa Fucα2Galβ4(Fucα3)GlcNAcβ3Galβ4GlcNAcβ3Galβ4Glcβ1Cer CBA, MS [20]
Ganglioseries
30. NeuAc-GM1 Galβ3GalNAcβ4(NeuAcα3)Galβ4Glcβ1Cer MS [21, 22]
30. NeuGc-GM1 Galβ3GalNAcβ4(NeuGcα3)Galβ4Glcβ1Cer MS [23]
31. GD1a NeuAcα3Galβ3GalNAcβ4(NeuAcα3)Galβ4Glcβ1Cer MS [10, 21]
aMethods used for characterization: TLC, thin-layer chromatography with chemical detection; MS, mass spectrometry; NMR, proton NMR; CBA,
chromatogram binding assays; IH, immunohistochemistry; EM, immune electron microscopy, FC, flow cytometry, IF, immunofluorescence
bGlycosphingolipids in italics have been characterized in only one study and by only one method
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Sialyl-lactotetraosylceramide
Sialyl-lactotetraosylceramide was characterized as a hESC
glycosphingolipid [10] by mass spectrometry (Fig. 1a), and
binding of anti-sialyl-lactotetra antibodies on thin-layer chro-
matograms (Fig. 1c). No binding of anti-sialyl-neolactotetra
antibodies to the acid glycosphingolipids of hESC was
obtained.
A high cell surface expression of sialyl-lactotetra on both
hESC and hiPSC was demonstrated by flow cytometry
(Fig. 1e), immunohistochemistry (Fig. 1f), and immune elec-
tron microscopy. Indeed, all seven hESC lines and three
hiPSC lines analyzed showed distinct cell surface anti-sialyl-
lactotetra staining by immunohistochemistry, whereas no
staining with anti-sialyl-neolactotetra was observed
(Fig. 1g). However, there was no staining of hESC-derived
hepatocyte-like or cardiomyocyte-like cells. Upon differenti-
ation into hepatocyte-like cells the sialyl-lactotetra epitope
was rapidly down-regulated and not detectable after 14 days.
The loss of sialyl-lactotetra upon differentiation occurred in
parallel with the reduced expression of the established
pluripotency markers SSEA-4 and TRA-1-60. Expression of
the sialyl-lactotetra epitope is also decreased in neuronal stem
cells differentiating from hiPSC (K. Säljö et al., in manu-
script). Taken together these findings identify sialyl-
lactotetra as a promising new marker of undifferentiated hu-
man pluripotent stem cells.
Sialyl-lactotetraosylceramide has not been identified in
adult human tissues, but is present in the brains of children
under the age of two [29], as well as in humanmeconium [30],
the first stool of the newborn consisting mainly of extruded
mucosal cells from the developing fetal gastrointestinal tract,
indicating that sialyl-lactotetraosylceramide is produced dur-




are also potential novel markers of human pluripotent stem cells.
These hESC glycosphingolipids were characterized by mass
spectrometry [10], and should be confirmed by other analytical
methods. Sulf-globopentaosylceramide has hitherto only been
ident i f ied in adul t human kidneys [31] . Sia lyl -
globotetraosylceramide has not been reported in normal human
tissues, but has been characterized in human teratocarcinoma
cells [32], and in muscles affected by amyothropic lateral
sclerosis [33]. Terminal NeuAcα3GalNAc is a rare sequence,
but is found in the s ia ly l -x2 g lycosphingol ip id
(NeuAcα3GalNAcβ3Galβ4GlcNAcβ3Galβ4Glcβ1Cer; [34]),
and α2,3-sialylation of the terminal GalNAc of x2 and
globotetraosylceramide by the α2,3-sialyltransferase ST3Gal II
has been demonstrated [35].
Development of specific reagents as e.g. monoclonal anti-
bodies specific for sulf-globopentaosylceramide and sialyl-
Fig. 1 Studies of the sialyl-lactotetra glycosphingolipid in hESC. (a)
MS2 spectrum of the [M-2H+]2− ion at m/z 758 from LC-ESI/MS of the
hESC ganglioside fraction 181C. The [M-2H+]2− ion at m/z 758
corresponds to a [M-H+]− ion at m/z 1517, and indicates a ganglioside
with one NeuAc, one HexNAc, three Hex, and d18:1–16:0 ceramide.
MS2 of the ion at m/z 758 gave spectrum with B- and C-type fragment
ions (B1 atm/z 290, C1 atm/z 308, C2 atm/z 470, B3 atm/z 655, C3 atm/z
673, B4 atm/z 817, C4 atm/z 835 and C5 atm/z 997), which together with
the Y0 ion at m/z 536, demonstrated a glycosphingolipid with NeuAc-
Hex-HexNAc-Hex-Hex carbohydrate sequence and d18:1–16:0
ceramide. Cross-ring 0,2A-type fragments are diagnostic for
carbohydrates substituted at C-4 [28]. The absence of a 0,2A3 fragment
ion at m/z 572 indicated a 3-substituted HexNAc. (b) Thin-layer
chromatogram stained by the chemical reagent anisaldehyde, and (c)
immunostained using the anti-sialyl-lactotetra antibody. Lane 1, hESC
SA181 acid glycosphingolipid fraction 181A, Lane 2, hESC SA181 acid
glycosphingolipid fraction 181B; Lane 3, hESC SA181 acid
glycosphingolipid fraction 181C. (d) Flow cytometry diagram of hESC
incubated with antibodies against SSEA-4 and (e) sialyl-lactotetra. (f)
Immunohistochemistry of hESC using anti-sialyl-lactotetra and (g) anti-
sialyl-neolactotetra antibodies
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globotetraosylceramide are urgently needed for studies of the
expression of these compounds during hPSC differentiation.
Non-acid glycosphingolipids of hESC
Blood group AB(O)H antigens
The ABO histo-blood group system is the strongest histocom-
patibility antigen system in human allotransplantation. Even if
successful ABO incompatible live donor renal allotransplan-
tation protocols have been introduced during the last decade
[36], this immunological barrier is still of significant impor-
tance. Clinical applications grafting hESC, and/or tissues de-
rived from these cells, will challenge the immune system of
the recipient with non-self antigens. Therefore, ABO typing of
hESC is important, and cell lines of blood group type O
should preferentially be used. A few years ago, we showed
for the first time that hESC lines expressed blood group A/B
antigens in concordance with the cells ABO genotypes [37].
There was also a slightly different expression of A and B
antigens, with B antigen mainly on the cell surface, while A
antigens were found both on the cell surface and in the cyto-
plasm. These cell lines were cultured on mouse feeder fibro-
blasts and cell amounts available were too small to allow any
chemical characterization.
A great structural diversity of blood group AB(O)H
glycosphingolipids are found in adult tissues/cells both
regarding number of carbohydrate residues and type of
core chains [38, 39]. Therefore a very interesting finding
was that the two hESC lines, both of blood group A1
genotype, expressed the A antigen determinant only as a
type 1 core chain hexaglycosylceramide [20]. This is in
contrast to the type 2 core chain based Lex and Ley deter-
minants, which were found on glycosphingolipids with
different chain lengths [20].
Blood groupH type 1 pentaosylceramidewas themajor blood
group compound in the two hESC lines in our study [20]. The H
type 1 chain determinant has been identified as a hPSC marker
denoted SSEA-5 [9], and recently a monoclonal antibody specif-
ic for the H type 1 pentaosylceramide was generated by immu-
nization with hiPSC, and shown to exhibit potent dose-
dependent cytotoxicity to the hiPSC [40]. The H type 1
pentaosylceramide was earlier identified in human meconium
[41], and also in meconium from a 17 weeks old fetus [42].
However, blood group H type 1 chain glycosphingolipids are
not specific for fetal tissues, since these compounds are present
in large amounts in adult human tissues, predominantly in endo-
dermal derived glandular epithelial tissues like pancreas [43] and
intestinal epithelium [38, 44]. In contrast, mesodermal-derived
organs lack, or have only small amounts of type 1 chain blood
group antigens [38].
Lewis and related antigens
The type 1 chain based Lea and Leb antigens are present in
large amounts in human tissues, similar to the blood group
ABH antigens described above [38]. These Lewis antigens
were identified in human fetuses from 37 mm of length [45],
and are present in large amounts in meconium [41]. Still Lea or
Leb glycosphingolipids have not been identified in any of the
hESC lines characterized [20–23], and the Lea or Leb deter-
minants are not detected by flow cytometry of several other
hESC and hiPSC lines (K. Säljö et al., in manuscript). This is
intriguing since only 20 % of Caucasians are Lewis negative.
The corresponding type 2 core chain glycosphingolipids
Lex and Ley were identified in the investigated hESC lines
[20]. Immunohistochemistry studies show that in human em-
bryos the expression of Lex and multimeric Lex peaks at spe-
cific developmental stage, mostly at 40–80 days, followed by
a decline upon further development [46]. Both compounds are
mainly found in gastrointestinal and urogenital epithelia, but
the tissue distribution of Lex is wider than for multimeric Lex.
Miyake et al. demonstrated a variation in expression of the
Lex, Ley and sialyl-Lea antigens during lung development of
human embryos [47]. Furthermore, the Lex and Ley determi-
nants have been found in adult human organs by immunohis-
tochemistry (reviewed in ref. [48]), and chemically identified
in glycoproteins [49] and glycosphingolipids [38, 50].
Are SSEA-1 and Lex identical antigen structures?
The presence of Lex sequences in undifferentiated hESC is a
controversial and confusing issue. The confusion is, at least
partly, caused by the marketing of the SSEA-1 defining anti-
body MC480 [51] as an antibody specific for the Lex deter-
minant as well as a differentiation marker. However, the anti-
bodyMC480 reactivity is restricted to the Lex epitope present-
ed on long type 2 core chains, as e.g. among the slow-
migrating non-acid glycosphingolipids of human erythrocytes
[50, 52].
No binding of the MC480 antibody to hESC is found by
immunohistochemistry or flow cytometry, indicating that
SSEA-1 is not expressed in undifferentiated hESC.
However, SSEA-1 is expressed upon initiation of cell differ-
entiation [3, 53]. The fact that the MC480/SSEA-1 antibody
does not bind to undifferentiated hESC has led to the interpre-
tation that there are no Lex glycoconjugates in these cells.
However, in the non-acid glycosphingolipid fractions of un-
differentiated hESC the MC480/SSEA-1 antibodies react with
several slow-migrating glycosphingolipids present in very
small amounts (Fig. 2a, lane 1). The anti-Lex antibody P12,
has the capacity to bind to the Lex pentaosylceramide
(Fig. 2b, lane 3), and also binds in the heptaosylceramide region
and to minor slow-migrating glycosphingolipids of the undif-
ferentiated hESC (Fig. 2b, lane 1). Furthermore, when
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undifferentiated hESC were analyzed by flow cytometry, the
P12 antibody gave distinct cell reactivity, while the MC480
antibody was negative (Fig. 2c). Taken together the mass spec-
trometry and antibody binding data thus demonstrate that
glycosphingolipids with terminal Lex sequences are present in
undifferentiated hESC. The Lex determinant has also been char-
acterized in hESC N-glycans [54]. Short chain Lex epitopes
recognized by the P12 antibody are readily detectable on the
cell surface, whereas Lex epitopes on long type 2 core chains
recognized by the MC480/SSEA-1 antibody are not. This
might be due to the very low amounts of these MC480 binding
compounds, or that these glycosphingolipids reside in intracel-
lular compartments and have not yet reached the cell surface.
Up-regulation of SSEA-1 expression upon differentiation
should thus correspond to an increased level of cell surface
glycoconjugates with terminal Lex determinants on long poly-
N-acetyllactosamine chains.
Since the beginning of stem cell research, the expression of
SSEA-1 has been considered to be a marker of differentiation
in human stem cells [3, 53]. However, in the cell lines ana-
lyzed by us an increased expression of SSEA-1 is only ob-
served during a short period after induction of differentiation,
as illustrated by the quite modest and transient increase of
SSEA-1 (clone MC480) expression during differentiation
from hESC into hepatocyte-like cells. Only a distinct subpop-
ulation (approximately 8 %) of the cells express SSEA-1 on
their cell surface on day 7 after induction of differentiation
(Fig. 3). A similar transient increase of SSEA-1 was observed
during neuronal differentiation of hESC [55]. SSEA-1 was
expressed during the neural stem cell stage (days 18–23 in
vitro), while more differentiated neural precursor cells (days
30–37 in vitro) were SSEA-1 negative. Therefore, in humans
SSEA-1 seems to be a differentiation marker for an early tran-
sient period, and not a general differentiation marker.
Ceramide composition of hESC glycosphingolipids
Sphingosine (d18:1) with non-hydroxy 16:0 fatty acid is the
main ceramide species of hESC glycosphingolipids, as deter-
mined by mass spectrometry [10, 20, 21]. In addition there are
minor species with sphingosine and non-hydroxy 18:0–24:0/
24:1 fatty acids, and among the sulfatides sphingosine with
hydroxy 16:0 and 18:0 fatty acids are also present. Thus, the
ceramide composition of hESC glycosphingolipids is relative-
ly simple in contrast to the structural diversity of ceramides
found in adult human tissues [14]. In e.g. adult human brain
gangliosides the major ceramides are d18:1–18:0 and d20:1–
18:0, whereas the epithelial cells of the human small intestine
have predominantly phytosphingosine (t18:0) with hydroxy
16:0–24:0 fatty acids.
Changes in hESC carbohydrate antigen expression
upon differentiation
The changes in hESC surface antigens upon differentiation
induced by retinoic acid, hexamethylene bisacetamide and
dimethylsulfoxide was studied by flow cytometry by Draper
et al. [56], demonstrating a rapid decrease in the expression of
SSEA-3 and SSEA-4 following all types of induction. There
was also an increased expression of several gangliosides, as
e.g. GT3 and 9-O-acetyl-GD3. A transient increase in the
expression of SSEA-1 was obtained by retinoic acid induc-
tion, but not with the other agents.
Similar patterns, i.e. decreased expression of globo-
se r i e s (SSEA-3 and Globo H) and lac to - se r i e s
(lactotetraosylceramide and H type 1 pentaosylceramide)
glycosphingolipids, and increased expression of the ganglio-
sides GM3, GM1 and GD3, were observed upon
Fig. 2 Binding of anti-SSEA-1 monoclonal antibody MC480 (a) and
anti-Lex monoclonal antibody P12 (b) to non-acid glycosphingolipids
of undifferentiated hESC. Lane 1, hESC SA181 non-acid
glycosphingolipid fraction IV; Lane 2, reference total non-acid
glycosphingolipids of human blood group AB erythrocytes; lane 3, ref-
erence Lex pentaosylceramide. (c) Flow cytometry diagram of hiPSC
incubated with antibodies against CD15 (C3D-1; grey), SSEA-1
(MC480; red), and Lex (P12; blue)
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differentiation of hESC toward neural progenitor cells [22]. In
contrast, a high expression of the globo-series (mainly
globotetraosylceramide) and lacto-series glycosphingolipids
remained after differentiation into endodermal cells, and in
this case there was no increase in ganglioside expression.
The expression of SSEA-5 and sialyl-lactotetra is also rapidly
reduced in differentiating cells [9, 10].
Studies on changes in cell surface glycan distribution in
the early development of human embryos are still very
limited. In the early 1960’s, Szulman described ABH and
Lewis antigen expression in a large number of fetuses from
5 to 14 weeks gestation age using immunohistochemistry
[45, 53]. An interesting variation, depending on the fetus
age, was demonstrated both regarding the cell wall located
and excreted ABH antigens. It was also shown that certain
tissues/cells of the fetuses, as e.g. cardiomyocytes and he-
patocytes of 18–24 mm human embryos, did not express
ABH antigens early in the development [57]. This is in
accordance with our finding that a blood group B hESC
line lost the B antigen expression upon differentiation into
cardiomyocyte like cells [37]. In the adult human heart and
liver, both cardiomyocytes and hepatocytes completely
lack ABH antigens, while vascular endothelium and bile
ducts do express ABH antigens. In a more recent study,
Henderson et al. showed by immunohistochemistry on hu-
man embryos that SSEA-3 and SSEA-4 are found in the
inner cell mass of expanded or hatching blastocysts,
whereas SSEA-1 is present in trophectoderm [53].
Final remarks
In recent years it has been possible to characterize the struc-
tures of human embryonic stem cell glycosphingolipids by
biochemical methods. The first s tudies of hESC
glycosphingolipids from crude lipid extracts [21, 22] allowed
identification of the major compounds of these cells as based
on g lobo core cha ins (g lobo te t raosy lce ramide ,
g l o b o p e n t a o s y l c e r a m i d e / S S EA - 3 , G l o b o H
hexaosylceramide, sialyl-globopentaosylceramide/SSEA-4
and di-sialyl-globopentaosylceramide), and type 1 core chains
(lactotetraosylceramide and fucosyl-lactotetraosylceramide/H
type 1 pentaosylceramide). In addition the gangliosides GM3,
GM1, GD1a or GD1b were found. A similar profile was de-
scribed in a recent study of hiPSC glycosphingolipids [58].
Start ing from considerably more hESC material ,
glycosphingolipid fractions could be isolated [10, 20] and, in
addition to the major compounds, it was also possible to iden-
tify minor glycosphingolipids, as e.g. type 2 core chain
glycosphingolipids and even some very rare minor acid
glycosphingolipids (sialyl-globotetraosylceramide and sulf-
globopentaosylceramide).
A remaining question is whether the carbohydrate ex-
pression of undifferentiated cells changes as a result of
differentiation, or if glycans influence or play a more direct
role in cellular destiny. The role of SSEA-3 and SSEA-4
glycosphingolipids in maintaining hESC pluripotency has
been investigated by blocking glycosphingolipid biosyn-
thesis in hESC using the inhibitors D-PDMP or ISP-1
(myriocin) [59]. hESC depleted of glycosphingolipids still
differentiated to ectodermal, endodermal, and mesodermal
lineages in vivo, and the gene expression profile of the cells
was not altered, demonstrating that glycosphingolipids do
not have a critical function in the maintenance of the un-
differentiated state of hESC. However, when embryoid
bodies were generated from hESC in the presence or ab-
sence of inhibitors, the gene expression profile of the em-
bryoid bodies from hESC depleted of glycosphingolipids
was distinctly different from the profile of control embry-
oid bodies, suggesting a role for glycosphingolipids during
cellular differentiation. Interestingly, targeted disruption of
the Ugcg gene encoding glucosylceramide synthase in
mice gave embryos that underwent implantation and at first
appeared to develop normally [60]. Gastrulation was initi-
ated in the mutant embryos with differentiation into em-
bryonic germlayers. However, at this stage an apoptotic
process resulted in embryonic death. Furthermore, the ca-
pacity of embryonic stem cells with disrupted Ugcg gene to
differentiate in vivo was severely impaired. Taken together
these studies demonstrate a role for glycosphingolipids
during embryonic development and differentiation of tis-
sues, possibly by influencing critical cell-cell and cell-
matrix interactions.
Fig. 3 (a) Flow cytometry analysis of cell surface expression of SSEA-1
(clone MC480) and SSEA-3 (clone MC631) on hESC line SA121 during
differentiation from hESC into hepatocyte-like cells (day 0, 7, 14 and 21).
(b) Flow cytometry diagram of hESC line SA121 incubated with anti-
bodies against SSEA-1 (MC480; red) on day 7 after induction of differ-
entiation into hepatocyte like cells. Approximately 8 % of the cells tran-
siently express SSEA-1 on day 7
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An important aspect in hPSC-derived cell replacement ther-
apy is the risk of tumorigenesis from residual undifferentiated
cells in the differentiated cell cultures [61]. Thus, sensitive as-
says to detect residual hPSC contamination in the differentiated
cell population and methods to eliminate contaminating undif-
ferentiated hPSC, are needed. Cell surface carbohydrate
markers of hPSC can be important tools for the selective re-
moval of undifferentiated hPSC [62]. The range of such carbo-
hydrate markers has now been extended by the creation of the
monoclonal antibody against the H type 1 glycosphingolipid
with potent dose-dependent cytotoxicity to hiPSC [40], which
may be used for elimination of undifferentiated cells. The re-
cently identified sialyl-lactotetra marker of undifferentiated
hPSC [10] may also be used for negative selection of undiffer-
entiated stem cells in therapeutic cell products.
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